chenodeoxycholic acid [Ligand Id: 608] activity data from GtoPdb and ChEMBL
Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
| ChEMBL ligand: CHEMBL240597 (Acide chenodesoxycholique, Acido quenodeoxicolico, Anthropodeoxycholic acid, Anthropodesoxycholic acid, Anthropododesoxycholic acid, Chendol, Chendol 125, Chendol 250, Chenic acid, Chenix, Chenocedon, Chenocol, Chenodeoxycholate, Chenodeoxycholic acid, Chenodeoxycholic acid leadiant (previously known as chenodeoxycholic acid sigma-tau), Chenodesoxycholic acid, Chenodiol, Chenofalk, Chenossil, Cholanorm, Combidol, Fluibil, Gallodesoxycholic acid, Lithofalk, NSC-657949, NSC-757798, Xenbilox) |
|---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
|
There should be some charts here, you may need to enable JavaScript!
|
| DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
|---|---|---|---|---|---|---|---|---|
| Beta-galactoside alpha-2,6-sialyltransferase 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3596075] [UniProtKB: P15907] | ||||||||
| ChEMBL | Inhibition of recombinant human N-terminal His tagged ST6GAL1 (44 to 406 residues) by UPLC-based assay | B | 4.3 | pIC50 | >50000 | nM | IC50 | Bioorg Med Chem Lett (2024) 105: 129760-129760 [PMID:38641151] |
| Farnesoid X receptor/Bile acid receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2047] [GtoPdb: 603] [UniProtKB: Q96RI1] | ||||||||
| ChEMBL | Activation of human farnesoid X receptor; range is 10-30 | B | 4.52 | pEC50 | 30000 | nM | EC50 | J Med Chem (2005) 48: 5383-5403 [PMID:16107136] |
| ChEMBL | Agonist activity at human recombinant FXR expressed in HEK293 cells coexpressing CMX-GAL4N by luciferase reporter gene assay | F | 4.57 | pEC50 | 27000 | nM | EC50 | Bioorg Med Chem Lett (2012) 22: 3962-3966 [PMID:22583617] |
| ChEMBL | Agonistic activity at FXR in HEK293 cells by GAL4 transactivation activity | F | 4.57 | pEC50 | 27000 | nM | EC50 | Bioorg Med Chem (2007) 15: 2587-2600 [PMID:17292610] |
| ChEMBL | Agonist activity at human GST-fused FXR LBD assessed as coactivator interaction with receptor ligand binding domain by Alphascreen assay | B | 4.68 | pEC50 | 21000 | nM | EC50 | Bioorg Med Chem (2011) 19: 2650-2658 [PMID:21459580] |
| ChEMBL | Transactivation of human FXR (unknown origin) expressed in HepG2 cells co-expressing pSG5RXR/pGL4.70 after 24 hrs post transfection by luciferase reporter gene assay | B | 4.7 | pEC50 | 20000 | nM | EC50 | ACS Med Chem Lett (2019) 10: 407-412 [PMID:30996771] |
| ChEMBL | Agonist activity at farnesoid x receptor(unknown origin) | B | 4.74 | pEC50 | 18000 | nM | EC50 | Bioorg Med Chem (2016) 24: 3232-3245 [PMID:27240466] |
| ChEMBL | Agonist activity at human FXR expressed in human HeLa cells assessed as receptor activation by BSEP promoter-driven firefly luciferase reporter gene assay | B | 4.74 | pEC50 | 18000 | nM | EC50 | J Med Chem (2014) 57: 8035-8055 [PMID:25255039] |
| ChEMBL | Agonist activity at human full length FXR expressed in HeLa cells cotransfected with pSG5-human RXR after 24 hrs by Dual-Glo luciferase reporter gene assay | B | 4.74 | pEC50 | 18000 | nM | EC50 | Bioorg Med Chem (2015) 23: 3490-3498 [PMID:25934227] |
| ChEMBL | Agonist activity at GST-tagged FXR-LBD (unknown origin) assessed as biotin-labeled SRC-1 recruitment after 30 mins by Alpha Screen assay | B | 4.82 | pEC50 | 15000 | nM | EC50 | Eur J Med Chem (2018) 144: 349-358 [PMID:29275233] |
| ChEMBL | Agonist activity at FXR expressed in COS1 cells by cell-based bioluminescence assay | F | 4.89 | pEC50 | 13000 | nM | EC50 | J Med Chem (2009) 52: 7958-7961 [PMID:20014870] |
| ChEMBL | Agonist activity at GST-tagged FXR-LBD using biotinylated-SRC-1 peptide as substrate preincubated with compound for 30 mins measured after 4 hrs | F | 4.89 | pEC50 | 13000 | nM | EC50 | ACS Med Chem Lett (2012) 3: 273-277 [PMID:24900463] |
| ChEMBL | Agonist activity at human FXR expressed in COS1 cells after 5 hrs by CRE-driven luciferase reporter gene assay | F | 4.89 | pEC50 | 13000 | nM | EC50 | J Med Chem (2007) 50: 4265-4268 [PMID:17685603] |
| ChEMBL | Agonist activity at FXR (unknown origin) | B | 4.89 | pEC50 | 13000 | nM | EC50 | Bioorg Med Chem (2016) 24: 3986-3993 [PMID:27372840] |
| ChEMBL | Agonist activity at human FXR expressed in COS1 cells by luciferase assay | F | 4.89 | pEC50 | 13000 | nM | EC50 | J Med Chem (2008) 51: 1831-1841 [PMID:18307294] |
| ChEMBL | Agonist activity at human recombinant FXR by transactivation of TK-MH100x4-LUC reporter gene in HEK293 cells | F | 4.93 | pEC50 | 11700 | nM | EC50 | Bioorg Med Chem Lett (2006) 16: 3213-3218 [PMID:16617018] |
| ChEMBL | Human FXR (NR1H4) Assay: The potency and efficacy of the compounds of the invention on TGR5 receptor was evaluated using in vitro assays which carried out using the express kit from DiscoverX (cAMP HUNTER eXpress GPBAR1 CHO-K1 GPCR Assay; Cataloguer number: 95-0049E2CP2S)GPBAR1 (G protein-coupled bile acid receptor 1) encodes a member of the G protein-coupled receptor (GPCR) superfamily. GPBAR1 activation following ligand binding initiates a series of second messenger cascades that result in a cellular response. Treatment of CHO cells expressing GPBAR1 with bile acids induces the production of intracellular cAMP and internalization of the receptor. The potency and efficacy of compound for GPBAR1 activation by measuring cyclic adenosine monophosphate (cyclic AMP or cAMP) levels in live cells using a competitive immunoassay based on Enzyme Fragment Complementation (EFC).In briefly, following seeding the cells into the white, 96 well microplate, place it in a 37° C., 5% CO2 in a humidified incubator for 18-24 hours prior to testing. On second day, proceed to the appropriate cAMP HUNTER eXpress Protocol according to the manufacturer's instructions. Dissolve agonist compound in DMSO at the desired stock concentration, and prepare 3-fold serial dilutions of agonist compound in Cell Assay Buffer. The concentration of each dilution should be prepared at 4× of the final screening concentration (i.e. 15 μL compound+45 μL Cell Assay Buffer/cAMP Antibody Reagent). For each dilution, the final concentration of solvent should remain constant. Transfer 15 μL diluted compound the assay plate and incubate the plate for 30 minutes at 37° C. Following agonist incubation, add 60 μL of working cAMP detection reagents/cAMP Solution mixture (cAMP Lysis Buffer, Substrate Reagent 1, cAMP Solution D) to the appropriate wells. Incubate for 1 hour at room temperature (23° C.), protected from light. Add 60 μl of cAMP Solution A to the appropriate wells. Incubate for 3 hours at room temperature (23° C.), protected from light. Read samples on Envision standard luminescence plate reader. Calculate of average EC50 after logarithm transformation. | B | 5 | pEC50 | >10000 | nM | EC50 | US-10208081-B2. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof (2019) |
| ChEMBL | Agonist activity at FXR | F | 5 | pEC50 | 10000 | nM | EC50 | Bioorg Med Chem (2011) 19: 6779-6791 [PMID:22014750] |
| ChEMBL | Agonist activity at glutathione transferase-tagged human FXR-LBD using biotinylated Src-1 peptide incubated for 30 mins by recruitment coactivator assay | B | 5 | pEC50 | 10000 | nM | EC50 | J Med Chem (2016) 59: 9201-9214 [PMID:27652492] |
| ChEMBL | Human FXR (NR1H4) Assay: The assay utilizes non-human mammalian cells, CHO (Chinese hamster ovary) cells engineered to express human NR1H4 protein (referred to as FXR). Reporter cells also incorporate the cDNA encoding beetle luciferase which catalyzes the substrates and yields photon emission. Luminescence intensity of the reaction is quantified using a plate-reading luminometer, Envision. Reporter Cells include the luciferase reporter gene functionally linked to an FXR responsive promoter. Thus, quantifying changes in luciferase expression in the treated reporter cells provides a sensitive surrogate measure of the changes in FXR activity. EC50 and efficacy (normalize to CDCA set as 100%) is determined by XLFit. The assay is according to the manufacturer's instructions. In brief, the assay was performed in white, 96 well plates using final volume of 100 ul containing cells with different doses of compounds. Retrieve Reporter Cells from −80° C. storage. Perform a rapid thaw of the frozen cells by transferring a 10 ml volume of 37° C. cell recovery medium into the tube of frozen cells. Recap the tube of Reporter Cells and immediately place it in a 37° C. water bath for 5-10 minutes. Retrieve the tube of Reporter Cell Suspension from the water bath. Sanitize the outside surface of the tube with a 70% alcohol swab, and then transfer it into the cell culture hood. Dispense 90 μl of cell suspension into each well of the 96-well Assay Plate. Transfer the plate into 37° C. incubator, allowing the cells adherent to the bottom of the well. Dilute compounds in Dilution Plate (DP), and administrate to cells at Assay Plate (AP). DMSO content of the samples was kept at 0.2%. Cells were incubated for additional 22 hours before luciferase activities were measured. Thirty minutes before intending to quantify FXR activity, remove Detection Substrate and Detection Buffer from the refrigerator and place them in a low-light area so that they may equilibrate to room temperature. Remove the plate's lid and discard all media contents by ejecting it into an appropriate waste container. Gently tap the inverted plate onto a clean absorbent paper towel to remove residual droplets. Cells will remain tightly adhered to well bottoms. Add 100 μl of luciferase detection reagent to each well of the assay plate. Allow the assay plate to rest at room temperature for at least 5 minutes following the addition of LDR. Set the instrument (Envision) to perform a single 5 second plate shake prior to reading the first assay well. Read time may be 0.5 second (500 mSec) per well. EC50 and Efficacy (normalize to CDCA set as 100%) is determined by XLFit.To assess the FXR agonistic potency of the exam | B | 5 | pEC50 | >10000 | nM | EC50 | US-10144729-B2. Isoxazole analogs as FXR agonists and methods of use thereof (2018) |
| ChEMBL | Human FXR (NR1H4) Assay: Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit purchased from Indigo Bioscience (Catalogue number: IB00601) to determine the potency and efficacy of compound developed by Enanta that can induce FXR activation. The principle application of this reporter assay system is to quantify functional activity of human FXR. The assay utilizes non-human mammalian cells, CHO (Chinese hamster ovary) cells engineered to express human NR1H4 protein (referred to as FXR). Reporter cells also incorporate the cDNA encoding beetle luciferase which catalyzes the substrates and yields photon emission. Luminescence intensity of the reaction is quantified using a plate-reading luminometer, Envision. Reporter Cells include the luciferase reporter gene functionally linked to an FXR responsive promoter. Thus, quantifying changes in luciferase expression in the treated reporter cells provides a sensitive surrogate measure of the changes in FXR activity. EC50 and efficacy (normalize to CDCA set as 100%) is determined by XLFit. The assay is according to the manufacturer's instructions. In brief, the assay was performed in white, 96 well plates using final volume of 100 μl containing cells with different doses of compounds. Retrieve Reporter Cells from −80° C. storage. Perform a rapid thaw of the frozen cells by transferring a 10 ml volume of 37° C. cell recovery medium into the tube of frozen cells. Recap the tube of Reporter Cells and immediately place it in a 37° C. water bath for 5-10 minutes. Retrieve the tube of Reporter Cell Suspension from the water bath. Sanitize the outside surface of the tube with a 70% alcohol swab, and then transfer it into the cell culture hood. Dispense 90 μl of cell suspension into each well of the 96-well Assay Plate. Transfer the plate into 37° C. incubator, allowing the cells adherent to the bottom of the well. Dilute compounds in Dilution Plate (DP), and administrate to cells at Assay Plate (AP). DMSO content of the samples was kept at 0.2%. Cells were incubated for additional 22 hours before luciferase activities were measured. Thirty minutes before intending to quantify FXR activity, remove Detection Substrate and Detection Buffer from the refrigerator and place them in a low-light area so that they may equilibrate to room temperature. Remove the plate's lid and discard all media contents by ejecting it into an appropriate waste container. Gently tap the inverted plate onto a clean absorbent paper towel to remove residual droplets. Cells will remain tightly adhered to well bottoms. Add 100 μl of luciferase detection reagent to each well of the assay plate. Allow the assay plate to rest at room temperature for at least 5 minutes following the addition of LDR. Set the instrument (Envision) to perform a single 5 second plate shake prior to reading the first assay well. Read time may be 0.5 second (500 mSec) per well. EC50 and Efficacy (normalize to CDCA set as 100%) is determined by XLFit. | B | 5 | pEC50 | >10000 | nM | EC50 | US-10149835-B2. Isoxazole derivatives as FXR agonists and methods of use thereof (2018) |
| ChEMBL | Agonist activity at FXR (unknown origin) assessed as recruitment of SRC1 peptide to FXR by FRET assay | B | 5.05 | pEC50 | 9000 | nM | EC50 | J Med Chem (2017) 60: 5235-5266 [PMID:28252961] |
| ChEMBL | Agonist activity at human FXR assessed as recruitment of SRC1 peptide by TR-FRET assay | B | 5.06 | pEC50 | 8660 | nM | EC50 | ACS Med Chem Lett (2017) 8: 1246-1251 [PMID:29259742] |
| ChEMBL | Effective concentration against Farnesoid X receptor (FXR) | B | 5.06 | pEC50 | 8660 | nM | EC50 | J Med Chem (2002) 45: 3569-3572 [PMID:12166927] |
| ChEMBL | Binding affinity for Farnesoid X Receptor (FXR) | B | 5.06 | pEC50 | 8660 | nM | EC50 | Bioorg Med Chem Lett (2003) 13: 1865-1868 [PMID:12749886] |
| ChEMBL | Agonist activity at FXR (unknown origin) | B | 5.06 | pEC50 | 8660 | nM | EC50 | J Med Chem (2020) 63: 5031-5073 [PMID:31930920] |
| ChEMBL | Binding affinity for human Farnesoid X receptor in FRET assay | B | 5.06 | pEC50 | 8660 | nM | EC50 | J Med Chem (2004) 47: 4559-4569 [PMID:15317466] |
| ChEMBL | Binding affinity to FXR assessed as ligand-dependent SRC1 recruitment by FRET based co-activator assay | F | 5.06 | pEC50 | 8660 | nM | EC50 | J Med Chem (2006) 49: 4208-4215 [PMID:16821780] |
| ChEMBL | Agonist activity at GST-tagged FXR-LBD (unknown origin) assessed as biotinylated SRC-1 recruitment after 30 mins by Alpha Screen assay | B | 5.1 | pEC50 | 8000 | nM | EC50 | Medchemcomm (2019) 10: 1412-1419 [PMID:31673308] |
| ChEMBL | Transactivation of full-length FXR (unknown origin) expressed in HEK293 cells after 18 hrs by dual-glo luciferase reporter gene assay | B | 5.15 | pEC50 | 7010 | nM | EC50 | Medchemcomm (2018) 9: 1630-1638 [PMID:30393515] |
| ChEMBL | Agonist activity at FXR assessed as activation by cell based luciferase transactivation assay | F | 5.2 | pEC50 | 6310 | nM | EC50 | Bioorg Med Chem Lett (2008) 18: 5497-5502 [PMID:18815030] |
| GtoPdb | - | - | 5.3 | pEC50 | - | - | - |
Science (1999) 284: 1365-8 [PMID:10334993]; Mol Cell (1999) 3: 543-53 [PMID:10360171] |
| ChEMBL | Effective concentration for recruitment of SRC-1 LxxLL-containing peptide to human Farnesoid X receptor | B | 5.46 | pEC50 | 3500 | nM | EC50 | J Med Chem (2005) 48: 5383-5403 [PMID:16107136] |
| ChEMBL | Ligand dependent recruitment of SRC1(676-700) peptide to human Farnesoid X-activated receptor by fluorescence resonance energy transfer assay | B | 5.47 | pEC50 | 3400 | nM | EC50 | J Med Chem (2000) 43: 2971-2974 [PMID:10956205] |
| ChEMBL | Human FXR (NR1H4) Assay: Determination of a ligand mediated Gal4 promoter driven transactivation to quantify ligand binding mediated activation of FXR. FXR Reporter Assay kit purchased from Indigo Bioscience (Catalogue number: IB00601) to determine the potency and efficacy of compound developed by Enanta that can induce FXR activation. The principle application of this reporter assay system is to quantify functional activity of human FXR. The assay utilizes non-human mammalian cells, CHO (Chinese hamster ovary) cells engineered to express human NR1H4 protein (referred to as FXR). Reporter cells also incorporate the cDNA encoding beetle luciferase which catalyzes the substrates and yields photon emission. Luminescence intensity of the reaction is quantified using a plate-reading luminometer, Envision. Reporter Cells include the luciferase reporter gene functionally linked to an FXR responsive promoter. Thus, quantifying changes in luciferase expression in the treated reporter cells provides a sensitive surrogate measure of the changes in FXR activity. EC50 and efficacy (normalize to CDCA set as 100%) is determined by XLFit. The assay is according to the manufacturer's instructions. In brief, the assay was performed in white, 96 well plates using final volume of 100 μl containing cells with different doses of compounds. Retrieve Reporter Cells from −80° C. storage. Perform a rapid thaw of the frozen cells by transferring a 10 ml volume of 37° C. cell recovery medium into the tube of frozen cells. Recap the tube of Reporter Cells and immediately place it in a 37° C. water bath for 5-10 minutes. Retrieve the tube of Reporter Cell Suspension from the water bath. Sanitize the outside surface of the tube with a 70% alcohol swab, and then transfer it into the cell culture hood. Dispense 90 μl of cell suspension into each well of the 96-well Assay Plate. Transfer the plate into 37° C. incubator, allowing the cells adherent to the bottom of the well. Dilute compounds in Dilution Plate (DP), and administrate to cells at Assay Plate (AP). DMSO content of the samples was kept at 0.2%. Cells were incubated for additional 22 hours before luciferase activities were measured. Thirty minutes before intending to quantify FXR activity, remove Detection Substrate and Detection Buffer from the refrigerator and place them in a low-light area so that they may equilibrate to room temperature. Remove the plate's lid and discard all media contents by ejecting it into an appropriate waste container. Gently tap the inverted plate onto a clean absorbent paper towel to remove residual droplets. Cells will remain tightly adhered to well bottoms. Add 100 μl of luciferase detection reagent to each well of the assay plate. Allow the assay plate to rest at room temperature for at least 5 minutes following the addition of LDR. Set the instrument (Envision) to perform a single 5 second ¿plate shake¿ prior to reading the first assay well. Read time may be 0.5 second (500 mSec) per well. EC50 and Efficacy (normalize to CDCA set as 100%) is determined by XLFit. | B | 6 | pEC50 | >1000 | nM | EC50 | US-10138228-B2. Isoxazole derivatives as FXR agonists and methods of use therof (2018) |
| Bile acid receptor in Mouse (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5343] [UniProtKB: Q60641] | ||||||||
| ChEMBL | Agonist activity at mouse FXR expressed in HEK293 cells co-expressing mouse RXRalpha and ECRE-luc by luciferase reporter gene assay | F | 4.77 | pEC50 | 16800 | nM | EC50 | Bioorg Med Chem (2011) 19: 7168-7180 [PMID:22018919] |
| Retinoid X receptor-α/Bile acid receptor/Retinoic acid receptor RXR-alpha in Mouse (target type: PROTEIN COMPLEX) [ChEMBL: CHEMBL3885529] [GtoPdb: 610] [UniProtKB: P28700, Q60641] | ||||||||
| ChEMBL | Agonist activity at full length mouse FXR/RXRalpha expressed in human HEK293 cells assessed as induction of transcriptional activity after 18 hrs by dual luciferase reporter gene assay | F | 4.77 | pEC50 | 16800 | nM | EC50 | Bioorg Med Chem (2011) 19: 6779-6791 [PMID:22014750] |
| GPBA receptor/G-protein coupled bile acid receptor 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5409] [GtoPdb: 37] [UniProtKB: Q8TDU6] | ||||||||
| ChEMBL | Agonist activity at TGR5 in human NCI-H716 cells assessed as increase in cAMP accumulation after 60 mins by HTR-FRET assay | F | 4.48 | pEC50 | 33000 | nM | EC50 | J Med Chem (2019) 62: 6824-6830 [PMID:31268316] |
| ChEMBL | Agonist activity at TGR5 in human NCI-H716 cells assessed as stimulation of intracellular cAMP accumulation incubated for 60 mins by HTR-FRET assay | F | 4.48 | pEC50 | 33000 | nM | EC50 | J Med Chem (2016) 59: 9201-9214 [PMID:27652492] |
| ChEMBL | Agonist activity at human TGR5 receptor expressed in NCI-H716 cells assessed as intracellular cAMP level by TR-FRET assay | F | 4.52 | pEC50 | 30000 | nM | EC50 | Bioorg Med Chem (2011) 19: 2650-2658 [PMID:21459580] |
| ChEMBL | Agonist activity at recombinant human TGR5 expressed in CHO cells assessed as increase in cAMP accumulation after 30 mins by TR-FRET assay | F | 4.81 | pEC50 | 15600 | nM | EC50 | J Med Chem (2019) 62: 6824-6830 [PMID:31268316] |
| ChEMBL | Agonist activity at wild type TGR5 (unknown origin) | B | 4.99 | pEC50 | 10290 | nM | EC50 | ACS Med Chem Lett (2013) 4: 1158-1162 [PMID:24900622] |
| ChEMBL | Agonist activity at human TGR5 expressed in CHO cells after 5 hrs by CRE-driven luciferase reporter gene assay | F | 5.17 | pEC50 | 6710 | nM | EC50 | J Med Chem (2007) 50: 4265-4268 [PMID:17685603] |
| ChEMBL | Agonist activity at human TGR5 expressed in CHO cells by luciferase assay | F | 5.17 | pEC50 | 6710 | nM | EC50 | J Med Chem (2008) 51: 1831-1841 [PMID:18307294] |
| ChEMBL | Agonist activity at TGR5 expressed in NCI-H716 cells assessed as cAMP level after 60 mins by FRET analysis | F | 5.17 | pEC50 | 6700 | nM | EC50 | ACS Med Chem Lett (2012) 3: 273-277 [PMID:24900463] |
| ChEMBL | Agonist activity at human GPBAR1 expressed in HEK293 cells assessed as increase in intracellular cAMP level after 30 mins by cAMP-Glo assay | F | 5.21 | pEC50 | 6100 | nM | EC50 | Bioorg Med Chem (2015) 23: 1613-1628 [PMID:25735208] |
| ChEMBL | Agonist activity at human TGR5 | F | 5.35 | pEC50 | 4430 | nM | EC50 | Eur J Med Chem (2024) 271: 116462-116462 [PMID:38691888] |
| GtoPdb | - | - | 5.4 | pEC50 | - | - | - | Biochem Biophys Res Commun (2002) 298: 714-9 [PMID:12419312] |
| Sodium/bile acid and sulphated solute cotransporter 2/Ileal sodium/bile acid cotransporter in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2778] [GtoPdb: 960] [UniProtKB: Q12908] | ||||||||
| ChEMBL | TP_TRANSPORTER: inhibition of Taurocholate uptake in ASBT-expressing COS cells | F | 5.48 | pKi | 3300 | nM | Ki | Am J Physiol (1998) 274: G157-G169 [PMID:9458785] |
| Plasmodium falciparum (target type: ORGANISM) [ChEMBL: CHEMBL364] | ||||||||
| ChEMBL | Antiplasmodial activity against Plasmodium falciparum 3D7 assessed as reduction in parasite viability by parasite lactate dehydrogenase assay | F | 4.72 | pIC50 | 18900 | nM | IC50 | Eur J Med Chem (2015) 100: 10-17 [PMID:26063305] |
| Vitamin D receptor/Vitamin D3 receptor in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1977] [GtoPdb: 605] [UniProtKB: P11473] | ||||||||
| ChEMBL | Antagonist activity against VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as inhibition of 1,25-dihydroxyvitamin D3-induced SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay | B | 4.3 | pIC50 | >50000 | nM | IC50 | Eur J Med Chem (2016) 109: 238-246 [PMID:26774929] |
| FPR1 in Human [GtoPdb: 222] [UniProtKB: P21462] | ||||||||
| GtoPdb | - | - | 4 | pKi | - | - | - | Inflamm Res (2000) 49: 744-55 [PMID:11211928] |
ChEMBL data shown on this page come from version 36:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]
